Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HBI-2376 / HUYA Bioscience
NCT06322095: A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors	Recruiting	2	72	RoW	PD-1, MET inhibitor, ALK inhibitor, BRAF Inhibito, EGFR Monoclonal antibody, GH21, MEK Inhibitor	Suzhou Genhouse Bio Co., Ltd.	Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations	09/25	12/25
NCT06306456: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC	Recruiting	1/2	94	RoW	GH21, Tagrisso	Suzhou Genhouse Bio Co., Ltd.	Non-Small Cell Lung Cancer With EGFR Mutation	12/25	12/26
NCT06435455: GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors	Not yet recruiting	1/2	126	NA	GH21, D-1553	Suzhou Genhouse Bio Co., Ltd., Zhejiang Cancer Hospital	Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation	09/27	12/27
NCT05183243: GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results	Recruiting	1	68	RoW	GH21 Capsule	Suzhou Genhouse Bio Co., Ltd.	Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Neoplasm	12/24	02/25
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations	Recruiting	1	42	US	HBI-2376	HUYABIO International, LLC.	Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon	12/24	12/24